相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down?
M. A. Nauck et al.
DIABETOLOGIA (2011)
Intact Glucagon-like Peptide-1 Levels are not Decreased in Japanese Patients with Type 2 Diabetes
Soushou Lee et al.
ENDOCRINE JOURNAL (2010)
Pioglitazone: side effect and safety profile
Priya Shah et al.
EXPERT OPINION ON DRUG SAFETY (2010)
Report of the Committee on the Classification and Diagnostic Criteria of Diabetes Mellitus
Yutaka Seino et al.
JOURNAL OF DIABETES INVESTIGATION (2010)
GIP and GLP-1, the two incretin hormones: Similarities and differences
Yutaka Seino et al.
JOURNAL OF DIABETES INVESTIGATION (2010)
Little enhancement of meal-induced glucagon-like peptide 1 secretion in Japanese: Comparison of type 2 diabetes patients and healthy controls
Daisuke Yabe et al.
JOURNAL OF DIABETES INVESTIGATION (2010)
Report of the Committee on the classification and diagnostic criteria of diabetes mellitus The Committee of the Japan Diabetes Society on the diagnostic criteria of diabetes mellitus
Yutaka Seino et al.
DIABETOLOGY INTERNATIONAL (2010)
Clinical results of treating type 2 diabetic patients with sitagliptin, vildagliptin or saxagliptin - diabetes control and potential adverse events
Bo Ahren
BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM (2009)
Current antihyperglycemic treatment strategies for patients with type 2 diabetes mellitus
L. BLONDE
CLEVELAND CLINIC JOURNAL OF MEDICINE (2009)
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study
Richard E. Pratley et al.
CURRENT MEDICAL RESEARCH AND OPINION (2009)
Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA1c without causing weight gain or increased hypoglycaemia
J. Rosenstock et al.
DIABETES OBESITY & METABOLISM (2009)
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy
R. E. Pratley et al.
DIABETES OBESITY & METABOLISM (2009)
Alogliptin: a new, highly selective dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes
Richard E. Pratley
EXPERT OPINION ON PHARMACOTHERAPY (2009)
Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study
M. A. Nauck et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2009)
Saxagliptin Added to a Thiazolidinedione Improves Glycemic Control in Patients with Type 2 Diabetes and Inadequate Control on Thiazolidinedione Alone
Priscilla Hollander et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2009)
Type 2 diabetes: Where we are today: An overview of disease burden, current treatments, and treatment strategies
R. Keith Campbell
JOURNAL OF THE AMERICAN PHARMACISTS ASSOCIATION (2009)
Fate of the beta-cell in the pathophysiology of type 2 diabetes
R. Keith Campbell
JOURNAL OF THE AMERICAN PHARMACISTS ASSOCIATION (2009)
Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes
David M. Nathan et al.
DIABETES CARE (2009)
Rosiglitazone no longer recommended
[Anonymous]
LANCET (2008)
Efficacy and Safety of the Dipeptidyl Peptidase-4 Inhibitor Alogliptin in Patients With Type 2 Diabetes and Inadequate Glycemic Control A randomized, double-blind, placebo-controlled study
Ralph A. DeFronzo et al.
DIABETES CARE (2008)
Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study
A. J. Garber et al.
DIABETES OBESITY & METABOLISM (2007)
分享论文
